Objective: Using a national data set, we sought to describe the population of patients for and the nature and timing of reinterventions after thoracic endovascular aortic repair (TEVAR) by aortic disease as well as by the impact on survival.
Methods: We evaluated the national data set for TEVAR in the Vascular Quality Initiative from 2010 to 2017. Student t-test and c 2 analysis were used to compare continuous and categorical variables in the reintervention and no reintervention groups, respectively. Freedom from reintervention and survival analysis was performed using Kaplan-Meier methods.
Results: A total of 6170 patients were evaluated: 51.2%, thoracic aortic aneurysm; 33.5%, type B dissection (TBD); 6.7%, trauma; 7.0%, penetrating aortic ulcer; and 1.6%, intramural hematoma. Overall, 477 (7.73%) underwent at least one reintervention, with an in-hospital reintervention rate of 3.29%. Reintervention patients were younger (64.4 6 14.5 vs 66.0 6 14.5 years; P ¼ .022) and more often transferred (37.7% vs 29.6%; P < .001), urgent (41.5% vs 33.6%; P ¼ .01), hypertensive (87.6% vs 83.8%; P ¼ .030), anticoagulated (14.0% vs 10.1%; P ¼ .007), symptomatic (54.3% vs 48.7%; P < .001), and ruptured (10.2% vs 6.5%; P < .001). In addition, the reintervention group exhibited more complexity with greater contrast material volume (130 6 81 vs 113 676 mL; P < .001), estimated blood loss (318 6 606 vs 281 6 517 mL; P ¼ .142), procedure time (183.5 6 128.0 vs 170.4 6 112.7 minutes; P ¼ .016), arm/neck access (28.9% vs 20.3%; P < .001), proximal deployment zones 0 to 2 (41.5% vs 16.9; P < .001), and larger mean proximal graft diameter (36.0 6 4.2 mm vs 34.1 6 5.4 mm; P ¼ .002). The reintervention group had more complicated postoperative courses marked by longer intensive care unit stays (6.5 6 7.4 vs 4.2 6 6.3 days; P < .001), total length of stay (16.1 6 35.0 vs 10.1 6 22.8 days; P < .001), more packed red blood cells (2.1 6 3.8 vs 1.2 6 3.1 units; P < .001), and vasopressor use (35.4% vs 23.8%; P < .001). Reinterventions were most commonly performed for TBD (12.4%), with reinterventions for other diseases occurring at lower rates: thoracic aortic aneurysm, 6.0%; intramural hematoma, 4.9%; penetrating aortic ulcer, 4.3%; and trauma, 1.7%. The most common cause of reintervention across all aortic diseases was type I endoleak. Other causes for reintervention by aortic disease are listed in the Table. Freedom from reintervention was decreased for TBD compared with other diseases (P < .001; Fig) . Whereas patients requiring in-hospital reinterventions suffered from increased mortality (P ¼ .05), there was no difference in survival in comparing patients undergoing reinterventions with those without (P ¼ .80).
Conclusions: Whereas reinterventions were not rare after TEVAR, there was no difference in mortality between patients undergoing reintervention and those without. Patients undergoing TEVAR for TBD demonstrated the highest reintervention rate. This study highlights the importance of long-term follow-up to address disease-specific patterns of reintervention.
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Type II Endoleak Incidence and Fate After Endovascular Aneurysm Repair by Low-Profile Polymer-Based Endograft Implantation in an Unselected Population* Objective: A potential correlation between the indication for low-profile endograft implantation and the incidence of type II endoleaks (T2ELs) after endovascular aneurysm repair (EVAR) of abdominal aortic aneurysms has been postulated. The aim of this study was to report the immediate and midterm incidence and fate of T2ELs in an unselected population of patients treated by EVAR using the Ovation stent graft (Endologix, Irvine, Calif) .
Methods: A retrospective study was conducted in three high-volume Italian vascular centers including 261 consecutive elective patients. Outcome measures were intraprocedural, immediate (30-day), 12-month, e94 Abstracts
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